Lead Product(s) : Iptacopan HCl
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis oral Fabhalta® (iptacopan) Receives Positive CHMP Opinion
Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients withC3 glomerulopathy.
Product Name : Fabhalta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2025
Lead Product(s) : Iptacopan HCl
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iptacopan HCl
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis Fabhalta Sustains Positive Phase 3 Results in C3 Glomerulopathy
Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients withC3 glomerulopathy.
Product Name : LNP023
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2024
Lead Product(s) : Iptacopan HCl
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis Shows Proteinuria Reduction Data from Atrasentan Phase III Trial in IgAN
Details : CHK-01 (atrasentan HCl) is an investigational oral endothelin A receptor antagonist (ERA), currently in Phase III development for IgAN and early-stage development for other rare kidney diseases
Product Name : CHK-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2024
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iptacopan HCl
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis Data Show Significant Proteinuria Reduction of 38.3% for IgA Nephropathy Patients
Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients with IgA nephropathy (IgAN).
Product Name : LNP023
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2024
Lead Product(s) : Iptacopan HCl
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iptacopan HCl
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LNP023 (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway being developed in Phase 3 for patients with C3 glomerulopathy, which met its primary endpoint by providing clinically meaningful and statistically significant proteinu...
Product Name : LNP023
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2023
Lead Product(s) : Iptacopan HCl
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CHK-01 (atrasentan hydrochloride) is an investigational oral endothelin A receptor antagonist (ERA), currently in Phase III development for IgAN and early-stage development for other rare kidney diseases
Product Name : CHK-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2023
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist is being evaluated phase 3 clinical trials for proteinuria reduction in patients with IgA nephropathy.
Product Name : CHK-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2023
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iptacopan HCl
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysi...
Product Name : LNP023
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2023
Lead Product(s) : Iptacopan HCl
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iptacopan HCl
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LNP023 (Iptacopan ), an oral, selective factor B inhibitor in patients with C3 glomerulopathy met primary endpoints in both patient cohorts. Iptacopan showed a favorable safety and tolerability profile in the Phase II final analysis, with no serious adve...
Product Name : LNP023
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 11, 2021
Lead Product(s) : Iptacopan HCl
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voclosporin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Aurinia Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Details : The dedicated facility will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial ...
Product Name : ISA247
Product Type : Peptide
Upfront Cash : Undisclosed
December 15, 2020
Lead Product(s) : Voclosporin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Aurinia Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration